Sudhir Srivastava

List of Publications by Year
in descending order

51 papers	4,269 citations	218677 26 h-index	197818 49 g-index
51 all docs	51 docs citations	51 times ranked	6557 citing authors

#	Article	IF	Citations
1	Î±-Fetoprotein, Des-Î³ Carboxyprothrombin, and Lectin-Bound Î±-Fetoprotein in Early Hepatocellular Carcinoma. Gastroenterology, 2009, 137, 110-118.	1.3	644
2	Addressing overdiagnosis and overtreatment in cancer: a prescription for change. Lancet Oncology, The, 2014, 15, e234-e242.	10.7	423
3	Evaluation of Serum Protein Profiling by Surface-Enhanced Laser Desorption/Ionization Time-of-Flight Mass Spectrometry for the Detection of Prostate Cancer: I. Assessment of Platform Reproducibility. Clinical Chemistry, 2005, 51, 102-112.	3.2	336
4	The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution. Cell, 2020, 181, 236-249.	28.9	334
5	Can Urinary PCA3 Supplement PSA in the Early Detection of Prostate Cancer?. Journal of Clinical Oncology, 2014, 32, 4066-4072.	1.6	234
6	Cancer overdiagnosis: a biological challenge and clinical dilemma. Nature Reviews Cancer, 2019, 19, 349-358.	28.4	220
7	A Prospective, Multicenter, National Cancer Institute Early Detection Research Network Study of [â^'2]proPSA: Improving Prostate Cancer Detection and Correlating with Cancer Aggressiveness. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 1193-1200.	2.5	186
8	Proteomics for cancer biomarker discovery. Clinical Chemistry, 2002, 48, 1160-9.	3.2	186
9	A high-stringency blueprint of the human proteome. Nature Communications, 2020, 11, 5301.	12.8	152
10	Epigenetics in cancer: implications for early detection and prevention. Lancet Oncology, The, 2002, 3, 755-763.	10.7	148
11	Association Between Combined TMPRSS2:ERG and PCA3 RNA Urinary Testing and Detection of Aggressive Prostate Cancer. JAMA Oncology, 2017, 3, 1085.	7.1	120
12	Challenges for Biomarkers in Cancer Detection. Annals of the New York Academy of Sciences, 2004, 1022, 9-16.	3.8	102
13	Keynote review: Recent advances in biomarkers for cancer diagnosis and treatment. Drug Discovery Today, 2005, 10, 965-976.	6.4	97
14	Proteomic analysis of cancer-cell mitochondria. Nature Reviews Cancer, 2003, 3, 789-795.	28.4	95
15	Biomarkers in molecular medicine: cancer detection and diagnosis. BioTechniques, 2005, 38, S9-S15.	1.8	91
16	Extracellular Vesicles in Cancer Detection: Hopes and Hypes. Trends in Cancer, 2021, 7, 122-133.	7.4	86
17	Synthetic biomarkers: a twenty-first century path to early cancer detection. Nature Reviews Cancer, 2021, 21, 655-668.	28.4	84
18	Nuclear accumulation of p53 in colorectal adenocarcinoma. Cancer, 1998, 83, 2456-2467.	4.1	70

#	Article	IF	Citations
19	New Cancer Biomarkers Deriving from NCI Early Detection Research. Recent Results in Cancer Research, 2003, 163, 72-84.	1.8	51
20	The Early Detection Research Network's Specimen Reference Sets: Paving the Way for Rapid Evaluation of Potential Biomarkers. Clinical Chemistry, 2013, 59, 68-74.	3.2	50
21	Early Detection Cancer Research Network. Laboratory Investigation, 2000, 80, 1147-1148.	3.7	48
22	New paradigms in translational science research inÂcancer biomarkers. Translational Research, 2012, 159, 343-353.	5.0	47
23	Proteomics in the Forefront of Cancer Biomarker Discoveryâ€. Journal of Proteome Research, 2005, 4, 1098-1103.	3.7	40
24	Generating a focused view of disease ontology cancer terms for pan-cancer data integration and analysis. Database: the Journal of Biological Databases and Curation, 2015, 2015, bav032-bav032.	3.0	40
25	The Making of a PreCancer Atlas: Promises, Challenges, and Opportunities. Trends in Cancer, 2018, 4, 523-536.	7.4	36
26	Definitive Characterization of CA 19-9 in Resectable Pancreatic Cancer Using a Reference Set of Serum and Plasma Specimens. PLoS ONE, 2015, 10, e0139049.	2.5	31
27	The Early Detection Research Network: 10-Year Outlook. Clinical Chemistry, 2013, 59, 60-67.	3.2	28
28	Early detection research program at the NCI. , 1996, 69, 35-37.		26
29	Systematic, evidence-based discovery of biomarkers at the NCI. Clinical and Experimental Metastasis, 2012, 29, 645-652.	3.3	22
30	The PreCancer Atlas (PCA). Trends in Cancer, 2018, 4, 513-514.	7.4	22
31	Leveraging Biospecimen Resources for Discovery or Validation of Markers for Early Cancer Detection. Journal of the National Cancer Institute, 2015, 107, .	6.3	20
32	Pan-Cancer Early Detection: Hype or Hope?. Cancer Cell, 2020, 38, 23-24.	16.8	20
33	Early Detection Initiative: A randomized controlled trial of algorithm-based screening in patients with new onset hyperglycemia and diabetes for early detection of pancreatic ductal adenocarcinoma. Contemporary Clinical Trials, 2022, 113, 106659.	1.8	20
34	Molecular diagnostics: a new frontier in cancer prevention. Expert Review of Molecular Diagnostics, 2004, 4, 503-511.	3.1	17
35	Research Needs for Understanding the Biology of Overdiagnosis in Cancer Screening. Journal of Cellular Physiology, 2016, 231, 1870-1875.	4.1	17
36	Rationale and design of the Hepatocellular carcinoma Early Detection Strategy study: A multi-center longitudinal initiative of the National Cancer Instituteâ€™s Early Detection Research Network. Contemporary Clinical Trials, 2019, 76, 49-54.	1.8	17

#	Article	IF	Citations
37	Cancer Biomarkers and Big Data: A Planetary Science Approach. Cancer Cell, 2020, 38, 757-760.	16.8	13
38	The Early Detection Research Network: A National Infrastructure to Support the Discovery, Development, and Validation of Cancer Biomarkers. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 2401-2410.	2.5	13
39	The Promise of Biomarkers in Colorectal Cancer Detection. Disease Markers, 2004, 20, 87-96.	1.3	11
40	Proteomic Maps of the Cancer-Associated Infectious Agentsâ€. Journal of Proteome Research, 2005, 4, 1171-1180.	3.7	11
41	Molecular Screening of Cancer. Molecular Diagnosis and Therapy, 2006, 10, 221-230.	3.8	10
42	Cancer biomarker discovery and development in gastrointestinal cancers: early detection research network-a collaborative approach. Gastrointestinal Cancer Research: GCR, 2007, 1, S60-3.	0.7	9
43	National Cancer Institute Think-Tank Meeting Report on Proteomic Cartography and Biomarkers at the Single-Cell Level: Interrogation of Premalignant Lesions. Journal of Proteome Research, 2020, 19, 1900-1912.	3.7	8
44	Biomarkers in oncology research and treatment: early detection research network: a collaborative approach. Biomarkers in Medicine, 2008, 2, 181-195.	1.4	7
45	Multicancer early detection test: Preclinical, translational, and clinical evidenceâ€“generation plan and provocative questions. Cancer, 2022, 128, 861-874.	4.1	7
46	Summarizing performance for genome scale measurement of miRNA: reference samples and metrics. BMC Genomics, 2018, 19, 180.	2.8	5
47	Risk-based and diagnostics-linked personalized medicine for cancer. Personalized Medicine, 2007, 4, 33-43.	1.5	4
48	Validation: a critical step in bringing biomarkers to clinical fruition. Annals of Epidemiology, 2018, 28, 135-138.	1.9	4
49	The National Cancer Institute Early Detection Research Network: Two Decades of Progress. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 2396-2400.	2.5	4
50	Molecular Detection and Diagnosis of Cancer. , 2017, , 797-809.		2
51	Systematic, Evidence-Based Discovery of Biomarkers at the National Cancer Institute. International Journal of Gynecological Cancer, 2012, 22, S41.	2.5	1